Endometrial Cancer

>

Latest News

Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.
Pembrolizumab/Chemo Receives OK From FDA in Advanced Endometrial Cancer

June 17th 2024

Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.

Data from the DUO-E trial support the FDA approval of durvalumab/chemotherapy for those with primary advanced or recurrent dMMR endometrial cancer.
FDA Approves Durvalumab/Chemo in dMMR Advanced Endometrial Cancer

June 14th 2024

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
Pembrolizumab Combo Does Not Reach DFS End Point in Endometrial Cancer

May 9th 2024

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.
Frontline Durvalumab Combo Improves PFS/DOR in Advanced Endometrial Cancer

March 19th 2024

More News


Site Logo

Surgical Staging in Endometrial Cancer

January 1st 2006

Early presentation of endometrial cancer permits effective managementwith excellent clinical outcome. The addition of hysteroscopy todilatation and curettage (D&C) in the evaluation of postmenopausalbleeding adds little to the detection of malignancy. Imaging studies suchas computed tomography, magnetic resonance imaging, and positronemissiontomography may be of use in determining the presence ofextrauterine disease in patients medically unfit for surgical staging.However, these studies are not sufficiently sensitive to replace surgicalstaging and have little role in routine preoperative evaluation. Clinicalstaging alone is clearly inadequate, as 23% of preoperative clinicalstage I/II patients are upstaged with comprehensive surgical staging.Preoperative tumor grade from D&C or office biopsy may be inaccurateand lead to an underestimate of tumor progression if used to determinewhich patients should be surgically staged. Clinical estimationof depth of invasion, with or without frozen section, is inaccurate andmay lead to underestimation of disease status when surgical staging isnot performed. The practice of resecting only clinically suspicious nodesshould be discouraged as it is no substitute for comprehensive surgicalstaging. Comprehensive surgical staging provides proper guidance forpostoperative adjuvant therapy, avoiding needless radiation in 85% ofclinical stage I/II patients. Finally, resection of occult metastasis withsurgical staging may improve survival.


Site Logo

What the Physician Needs to Know About Lynch Syndrome: An Update

April 1st 2005

The Lynch syndrome (hereditary nonpolyposis colorectal cancer[HNPCC]), is the most common form of hereditary colorectal cancer(CRC), accounting for 2% to 7% of all CRC cases. The next most commonhereditary CRC syndrome is familial adenomatous polyposis (FAP),which accounts for less than 1% of all CRC. Lynch syndrome is ofcrucial clinical importance due to the fact that it predicts the lifetimerisk for CRC and a litany of extra-CRC cancers (of the endometrium,ovary, stomach, small bowel, hepatobiliary tract, upper uroepithelialtract, and brain) through assessment of a well-orchestrated family history.A Lynch syndrome diagnosis is almost certain when a mutation ina mismatch repair gene-most commonly MSH2, MLH1, or, to a lesserdegree, MSH6-is identified. Once diagnosed, the potential for significantreduction in cancer-related morbidity and mortality through highlytargeted surveillance may be profound. Particularly important iscolonoscopy initiated at an early age (ie, 25 years) and repeated annuallydue to accelerated carcinogenesis. In women, endometrial aspirationbiopsy and transvaginal ultrasound are important given the extraordinarilyhigh risk for endometrial and ovarian carcinoma. Thesecancer control strategies have a major impact on at-risk family membersonce they have been counseled and educated thoroughly aboutLynch syndrome’s natural history and their own hereditary cancer risk.